Recent advances in cholesterol lowering medications
Pro Research Analysisby 
Searched over 200M research papers
Statins and Their Limitations in Cholesterol Lowering
Statins have been the mainstay of cholesterol-lowering therapy for decades, significantly reducing cardiovascular events and mortality by inhibiting HMG-CoA reductase, a key enzyme in cholesterol synthesis Ferri2024Abdul-Rahman2022Crîşmaru2020+1 MORE. However, some patients experience side effects such as muscle pain or do not achieve sufficient LDL cholesterol reduction with statins alone, highlighting the need for alternative or additional therapies Cupido2017Abdul-Rahman2022Crîşmaru2020.
PCSK9 Inhibitors: Monoclonal Antibodies and RNA-Based Therapies
A major recent advance is the development of PCSK9 inhibitors, including monoclonal antibodies like alirocumab and evolocumab, which can lower LDL cholesterol by 50–60% and are approved for patients with familial hypercholesterolemia or those not reaching targets with standard therapy Larsen2019Ajufo2016Cupido2017+5 MORE. More recently, small-interfering RNA (siRNA) therapies such as inclisiran have been approved, offering robust LDL reduction with infrequent dosing, similar to a vaccine-like schedule Larsen2019Ferri2024Abdul-Rahman2022+3 MORE.
New Oral Agents: Bempedoic Acid and Ezetimibe
Bempedoic acid, an oral ATP citrate lyase inhibitor, is a newly approved drug that lowers LDL cholesterol and reduces cardiovascular events, especially in patients who cannot tolerate statins Ferri2024Abdul-Rahman2022Luo2022+1 MORE. Ezetimibe, which inhibits intestinal cholesterol absorption, remains an important adjunct or alternative to statins, particularly for those needing further LDL reduction Ferri2024Abdul-Rahman2022Luo2022+2 MORE.
Therapies for Genetic and Complex Lipid Disorders
For patients with genetic lipid disorders, such as homozygous familial hypercholesterolemia, drugs like lomitapide and mipomersen inhibit LDL production but may increase liver fat and are reserved for specific cases Ajufo2016Cupido2017Ferri2024+2 MORE. Evinacumab, targeting angiopoietin-like 3 protein, and antisense oligonucleotides for lipoprotein(a) are emerging options for complex or refractory cases Abdul-Rahman2022Luo2022Parham2022.
Expanding Targets: Lp(a), Triglyceride-Rich Lipoproteins, and Gene-Based Therapies
Recent research is exploring therapies that target lipoprotein(a) [Lp(a)] and triglyceride-rich lipoproteins, which may further reduce cardiovascular risk in select patients Larsen2019Abdul-Rahman2022Luo2022+1 MORE. Gene-based therapies, including antisense oligonucleotides, adeno-associated virus vectors, and CRISPR/Cas9, are under investigation and may offer future options for patients with difficult-to-treat lipid disorders Abdul-Rahman2022Parham2022Khvorova2017.
Combination and Adjunctive Therapies
When LDL targets are not achieved with statins alone, combination therapy with agents such as ezetimibe, bile acid sequestrants, fibrates, or omega-3 fatty acids is recommended, especially in patients with mixed dyslipidemia Crîşmaru2020Ascaso2010. These combinations can help tailor treatment to individual risk profiles and lipid abnormalities.
Conclusion
Recent advances in cholesterol-lowering medications have expanded the therapeutic landscape beyond statins, with PCSK9 inhibitors, RNA-based drugs, bempedoic acid, and other novel agents offering new hope for patients at high cardiovascular risk or those intolerant to traditional therapies. Ongoing research into gene-based and targeted therapies promises even more personalized and effective options in the near future Larsen2019Ajufo2016Cupido2017+7 MORE.
Sources and full results
Most relevant research papers on this topic